Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 2/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4609744 | 0.98 | LMNA (0.65) | LMNAHTTSMN1; SMN2MAPK1POLB | |
| SCHEMBL6927327 | 0.86 | LMNA (0.69) | LMNAHTTSMN1; SMN2MAPK1POLB | |
| SCHEMBL10153812 | 0.85 | TSHR (0.61) | LMNAHTTSMN1; SMN2MAPK1TSHR | |
| SCHEMBL10490051 | 0.84 | L3MBTL1 (0.50) | LMNAHTTSMN1; SMN2MAPK1POLB | |
| SCHEMBL4180372 | 0.84 | KMT2A (0.61) | LMNAHTTSMN1; SMN2MAPK1POLB | |
| SCHEMBL1815207 | 0.84 | CA1 (0.73) | LMNAHTTSMN1; SMN2CA12CA9 | |
| SCHEMBL10154347 | 0.84 | LMNA (0.64) | LMNAHTTSMN1; SMN2POLBTSHR | |
| SCHEMBL4926851 | 0.84 | POLB (0.62) | LMNAHTTSMN1; SMN2POLBTSHR | |
| SCHEMBL29288591 | 0.83 | LMNA (0.65) | LMNAHTTSMN1; SMN2MAPK1POLB | |
| SCHEMBL15880603 | 0.83 | CA1 (0.73) | LMNAHTTSMN1; SMN2MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1976498-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
| CN-1434802-A | New azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| CN-1434870-A | Viral core protein-cationic lipid-nucleic acid-delivery complexes | MITSUBISHI PHARMACEUTICALS INC (JP) | 2003-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | LMNA 4381/4885HTT 4317/4885SMN1; SMN2 4237/4885 |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | LMNA 501/4885HTT 108/4885SMN1; SMN2 1114/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | LMNA 501/4885HTT 108/4885SMN1; SMN2 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.